Reza Tabrizi1, Maryam Akbari1, Nasrin Sharifi2, Kamran B Lankarani3, Mahmood Moosazadeh4, Fariba Kolahdooz5, Mohsen Taghizadeh2, Zatollah Asemi6. 1. Health Policy Research Center, Institute of Health, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Islamic Republic of Iran. 2. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran. 3. Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Islamic Republic of Iran. 4. Health Sciences Research Center, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Islamic Republic of Iran. 5. Indigenous and Global Health Research, Department of Medicine, University of Alberta, Edmonton, Canada. 6. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran. asemi_r@yahoo.com.
Abstract
INTRODUCTION: Although several trials have assessed the effect of coenzyme Q10 (CoQ10) supplementation on blood pressures among patients with metabolic diseases, findings are controversial. AIM: This review of randomized controlled trials (RCTs) was performed to summarize the evidence on the effects of CoQ10 supplementation on blood pressures among patients with metabolic diseases. METHODS: Randomized-controlled trials (RCTs) published in PubMed, EMBASE, Web of Science and Cochrane Library databases up to 10 August 2017 were searched. Two review authors independently assessed study eligibility, extracted data, and evaluated risk of bias of included studies. Heterogeneity was measured with a Q-test and with I2 statistics. Data were pooled by using the fix or random-effect model based on the heterogeneity test results and expressed as standardized mean difference (SMD) with 95% confidence interval (CI). RESULTS: A total of seventeen randomized controlled trials (684 participants) were included. Results showed that CoQ10 supplementation significantly decreased systolic blood pressure (SBP) (SMD - 0.30; 95% CI - 0.52, - 0.08). However, CoQ10 supplementation decreased diastolic blood pressure (DBP), but this was not statistically significant (SMD - 0.08; 95% CI - 0.46, 0.29). CONCLUSIONS: CoQ10 supplementation may result in reduction in SBP levels, but did not affect DBP levels among patients with metabolic diseases. Additional prospective studies regarding the effect of CoQ10 supplementation on blood pressure in patients with metabolic diseases are necessary.
INTRODUCTION: Although several trials have assessed the effect of coenzyme Q10 (CoQ10) supplementation on blood pressures among patients with metabolic diseases, findings are controversial. AIM: This review of randomized controlled trials (RCTs) was performed to summarize the evidence on the effects of CoQ10 supplementation on blood pressures among patients with metabolic diseases. METHODS: Randomized-controlled trials (RCTs) published in PubMed, EMBASE, Web of Science and Cochrane Library databases up to 10 August 2017 were searched. Two review authors independently assessed study eligibility, extracted data, and evaluated risk of bias of included studies. Heterogeneity was measured with a Q-test and with I2 statistics. Data were pooled by using the fix or random-effect model based on the heterogeneity test results and expressed as standardized mean difference (SMD) with 95% confidence interval (CI). RESULTS: A total of seventeen randomized controlled trials (684 participants) were included. Results showed that CoQ10 supplementation significantly decreased systolic blood pressure (SBP) (SMD - 0.30; 95% CI - 0.52, - 0.08). However, CoQ10 supplementation decreased diastolic blood pressure (DBP), but this was not statistically significant (SMD - 0.08; 95% CI - 0.46, 0.29). CONCLUSIONS:CoQ10 supplementation may result in reduction in SBP levels, but did not affect DBP levels among patients with metabolic diseases. Additional prospective studies regarding the effect of CoQ10 supplementation on blood pressure in patients with metabolic diseases are necessary.
Authors: Orhan Ates; Habip Bilen; Sadullah Keles; H Hakan Alp; Mevlüt Sait Keleş; Kenan Yıldırım; Osman Ondaş; L Can Pınar; Mustafa Civelekler; Orhan Baykal Journal: Int J Ophthalmol Date: 2013-10-18 Impact factor: 1.779
Authors: Gerard T Chew; Gerald F Watts; Timothy M E Davis; Bronwyn G A Stuckey; Lawrence J Beilin; Peter L Thompson; Valerie Burke; Philip J Currie Journal: Diabetes Care Date: 2008-05-16 Impact factor: 19.112
Authors: Juan M Suárez-Rivero; Carmen J Pastor-Maldonado; Mario de la Mata; Marina Villanueva-Paz; Suleva Povea-Cabello; Mónica Álvarez-Córdoba; Irene Villalón-García; Alejandra Suárez-Carrillo; Marta Talaverón-Rey; Manuel Munuera; José A Sánchez-Alcázar Journal: Int J Mol Sci Date: 2019-10-20 Impact factor: 5.923